Investor Presentation Q1-Q3 2020

7 Investor presentation First nine months of 2020 Diabetes value market leadership continues to expand 60% Novo Nordisk global diabetes value market share Diabetes GLP-1 Insulin Novo NordiskⓇ Diabetes value market leadership expansion driven by the GLP-1 and insulin franchises GLP-1 value market share has increased by ~3%-points since 2019, driven by: 49.9% 50% 48.8% • OzempicⓇ launched in 48 countries 46.7% 44.5% 42.4% 44.3% 40% 30% 27.4% 20% 2018 28.4% 29.2% 2019 2020 New generation insulins include: Tresiba®, Ryzodeg®, FiaspⓇ and XultophyⓇ CER: Constant exchange rates Source: IQVIA MAT, Aug 2020 Note: Unless otherwise specified, sales growth are at CER Uptake of OzempicⓇ and launch of Rybelsus® in North America Operations Insulin value market share has increased by 0.2%-points since 2019, driven by: New-generation insulins in International Operations facilitated by our Market Fit approach

View entire presentation